drugset / Trial / NCT05797883
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-12-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Levoleucovorin | Unknown | 200 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |